PolyMed Biopharma Licenses HPB-143 to Photys Therapeutics for Global Development
PolyMed Biopharma, a Hangzhou-based developer of Proteolysis Targeting Chimera (PROTAC) drugs, has entered into a...
Photys Therapeutics
Photys Therapeutics and Novo Nordisk Partner to Develop Proximity-Based Therapies for Cardiometabolic Diseases
US-based Photys Therapeutics, Inc. has entered into an agreement with Denmark-based Novo Nordisk A/S (NYSE:...